Loren Laine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Loren Laine has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
- Dennis Legen Shung
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Department of Artificial Intelligence and Informatics, Mayo Clinic, Rochester, MN, USA
10 shared publications Barbara Hunt
Phathom Pharmaceuticals, Buffalo Grove, IL, USA
4 shared publications- Harry R. Aslanian
Yale University
4 shared publications Liam Zakko
Connecticut Clinical Research Institute, Connecticut GI, Bristol, USA
4 shared publications- Priya A. Jamidar
Yale University School of Medicine
4 shared publications - Alan N. Barkun
Division of Gastroenterology, McGill University Health Center, McGill University, Montreal, Quebec, Canada
3 shared publications
Latest Publications
- 16 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Incidence and Risk Factors for C. difficile Reinfection After Faecal Microbiota Transplantation or Antibiotic Therapy
Background: Faecal microbiota transplant (FMT) is an effective treatment for multiply recurrent C. difficile infection (mrCDI). Less is known about rates of reinfection after successful FMT. We aimed to estimate the incidence of CDI reinfection, 6 or more months after FMT, to determine whether rates differ between mrCDI treated with and without FMT and whether proton pump inhibitor (PPI) therapy increases the risk of reinfection. Methods: Among patients with mrCDI (defined as ≥ 2 recurrences after the initial CDI episode) we compared reinfection with CDI (defined as a first recurrence > 183 days after treatment completion) in patients who underwent antibiotics followed by FMT with those treated with antibiotics alone in Optum's de‐identified Clinformatics Data Mart Database (OPTUM CDM). We also compared reinfection between those with and without PPI use in OPTUM CDM and the American Gastroenterological Association FMT Registry. Results: In OPTUM CDM, 6384 patients treated with antibiotics alone and 1786 with antibiotics + FMT met inclusion criteria (median follow‐up 704 days). One‐year and 3‐year CDI reinfection incidences were 5% and 10% in the FMT group and 6% and 12% in the antibiotics group: Cox regression HR 0.89, 95% CI 0.73–1.08. PPI use was associated with an increased risk of reinfection following FMT (HR 1.57, 1.03–2.41) in OPTUM CDM and in the FMT Registry (HR 1.62, 95% CI 0.84–3.12). Conclusions: CDI reinfection rates are low after successful FMT and similar to rates in patients treated with antibiotics alone. PPI use was associated with reinfection, supporting reassessment of the ongoing indication for PPI therapy in patients with mrCDI.
- 16 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Incidence and Risk Factors for C. difficile Reinfection After Faecal Microbiota Transplantation or Antibiotic Therapy
Background: Faecal microbiota transplant (FMT) is an effective treatment for multiply recurrent C. difficile infection (mrCDI). Less is known about rates of reinfection after successful FMT. We aimed to estimate the incidence of CDI reinfection, 6 or more months after FMT, to determine whether rates differ between mrCDI treated with and without FMT and whether proton pump inhibitor (PPI) therapy increases the risk of reinfection. Methods: Among patients with mrCDI (defined as ≥ 2 recurrences after the initial CDI episode) we compared reinfection with CDI (defined as a first recurrence > 183 days after treatment completion) in patients who underwent antibiotics followed by FMT with those treated with antibiotics alone in Optum's de‐identified Clinformatics Data Mart Database (OPTUM CDM). We also compared reinfection between those with and without PPI use in OPTUM CDM and the American Gastroenterological Association FMT Registry. Results: In OPTUM CDM, 6384 patients treated with antibiotics alone and 1786 with antibiotics + FMT met inclusion criteria (median follow‐up 704 days). One‐year and 3‐year CDI reinfection incidences were 5% and 10% in the FMT group and 6% and 12% in the antibiotics group: Cox regression HR 0.89, 95% CI 0.73–1.08. PPI use was associated with an increased risk of reinfection following FMT (HR 1.57, 1.03–2.41) in OPTUM CDM and in the FMT Registry (HR 1.62, 95% CI 0.84–3.12). Conclusions: CDI reinfection rates are low after successful FMT and similar to rates in patients treated with antibiotics alone. PPI use was associated with reinfection, supporting reassessment of the ongoing indication for PPI therapy in patients with mrCDI.
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Open AccessCoated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- 21 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5683-5690
Epidemiology of Acute Colonic Pseudo-obstruction (Ogilvie Syndrome) Based on Disease-Specific Data
- 21 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5683-5690
Epidemiology of Acute Colonic Pseudo-obstruction (Ogilvie Syndrome) Based on Disease-Specific Data
- 19 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (12) , 1646-1657
Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
Background: Antiplatelet management in patients hospitalised for gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI) requires balancing risks of rebleeding and clinical vascular events. Aims: Evaluate the impact of antiplatelet resumption timing post‐endoscopy on rebleeding and clinical vascular events. Methods: We performed a retrospective nationwide cohort study of patients hospitalised with post‐PCI GIB on dual antiplatelet therapy (DAPT) using the Vizient Clinical Database. Co‐primary outcomes were 30‐day rebleeding and 90‐day clinical vascular events after endoscopy. Multivariable Cox proportional hazards regression analysis was performed. Results: Among 2979 patients with both antiplatelet agents held before endoscopy for GIB (46.0% upper; 34.8% lower), antiplatelet resumption > 7 days post‐endoscopy was associated with decreased 30‐day rebleeding (hazard ratio [HR] 0.66; 95% confidence interval [CI] [0.49–0.87]) and increased 90‐day clinical vascular events (HR 1.18 [1.02–1.36]) compared to restarting ≤ 1 day post‐endoscopy. Among 869 patients with one antiplatelet agent held before endoscopy for GIB (47.3% upper; 36.3% lower), resumption at > 7 days vs. ≤ 1 day had HR 0.69 (0.41–1.14) for rebleeding and HR 1.41 (0.97–2.04) for clinical vascular events. HRs for antiplatelet resumption > 3 days vs. ≤ 1 day post‐endoscopy were similar. Conclusions: Antiplatelet resumption > 7 days after endoscopy in patients hospitalised with post‐PCI GIB is associated with decreased 30‐day rebleeding but increased 90‐day clinical vascular events compared with resumption ≤ 1 day post‐endoscopy. Similar tradeoffs were noted with antiplatelet resumption > 3 days post‐endoscopy. To optimise competing risks of rebleeding versus clinical vascular events, antiplatelet therapy should be resumed no later than 7 days post‐endoscopy, and preferably within 3–4 days.
- 19 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (12) , 1646-1657
Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
Background: Antiplatelet management in patients hospitalised for gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI) requires balancing risks of rebleeding and clinical vascular events. Aims: Evaluate the impact of antiplatelet resumption timing post‐endoscopy on rebleeding and clinical vascular events. Methods: We performed a retrospective nationwide cohort study of patients hospitalised with post‐PCI GIB on dual antiplatelet therapy (DAPT) using the Vizient Clinical Database. Co‐primary outcomes were 30‐day rebleeding and 90‐day clinical vascular events after endoscopy. Multivariable Cox proportional hazards regression analysis was performed. Results: Among 2979 patients with both antiplatelet agents held before endoscopy for GIB (46.0% upper; 34.8% lower), antiplatelet resumption > 7 days post‐endoscopy was associated with decreased 30‐day rebleeding (hazard ratio [HR] 0.66; 95% confidence interval [CI] [0.49–0.87]) and increased 90‐day clinical vascular events (HR 1.18 [1.02–1.36]) compared to restarting ≤ 1 day post‐endoscopy. Among 869 patients with one antiplatelet agent held before endoscopy for GIB (47.3% upper; 36.3% lower), resumption at > 7 days vs. ≤ 1 day had HR 0.69 (0.41–1.14) for rebleeding and HR 1.41 (0.97–2.04) for clinical vascular events. HRs for antiplatelet resumption > 3 days vs. ≤ 1 day post‐endoscopy were similar. Conclusions: Antiplatelet resumption > 7 days after endoscopy in patients hospitalised with post‐PCI GIB is associated with decreased 30‐day rebleeding but increased 90‐day clinical vascular events compared with resumption ≤ 1 day post‐endoscopy. Similar tradeoffs were noted with antiplatelet resumption > 3 days post‐endoscopy. To optimise competing risks of rebleeding versus clinical vascular events, antiplatelet therapy should be resumed no later than 7 days post‐endoscopy, and preferably within 3–4 days.
- 9 February 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (6) , 1112-1120
Topical hemostatic therapies for endoscopic treatment of nonvariceal gastrointestinal bleeding
- 9 February 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (6) , 1112-1120
Topical hemostatic therapies for endoscopic treatment of nonvariceal gastrointestinal bleeding
- Open Access
- 14 May 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 22 (11) , 2211-2220.e10
Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
- 14 May 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 22 (11) , 2211-2220.e10
Open AccessVonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
- Top Cited PapersOpen Access
- 11 May 2024
- Published by Association for Computing Machinery (ACM)
- p. 1-20
Human-Algorithmic Interaction Using a Large Language Model-Augmented Artificial Intelligence Clinical Decision Support System
Integration of artificial intelligence (AI) into clinical decision support systems (CDSS) poses a socio-technological challenge that is impacted by usability, trust, and human-computer interaction (HCI). AI-CDSS interventions have shown limited benefit in clinical outcomes, which may be due to insufficient understanding of how health-care providers interact with AI systems. Large language models (LLMs) have the potential to enhance AI-CDSS, but haven’t been studied in either simulated or real-world clinical scenarios. We present findings from a randomized controlled trial deploying AI-CDSS for the management of upper gastrointestinal bleeding (UGIB) with and without an LLM interface within realistic clinical simulations for physician and medical student participants. We find evidence that LLM augmentation improves ease-of-use, that LLM-generated responses with citations improve trust, and HCI varies based on clinical expertise. Qualitative themes from interviews suggest the perception of LLM-augmented AI-CDSS as a team-member used to confirm initial clinical intuitions and help evaluate borderline decisions.
- 11 May 2024
- Published by Association for Computing Machinery (ACM)
- p. 1-20
Top Cited PapersOpen AccessHuman-Algorithmic Interaction Using a Large Language Model-Augmented Artificial Intelligence Clinical Decision Support System
Integration of artificial intelligence (AI) into clinical decision support systems (CDSS) poses a socio-technological challenge that is impacted by usability, trust, and human-computer interaction (HCI). AI-CDSS interventions have shown limited benefit in clinical outcomes, which may be due to insufficient understanding of how health-care providers interact with AI systems. Large language models (LLMs) have the potential to enhance AI-CDSS, but haven’t been studied in either simulated or real-world clinical scenarios. We present findings from a randomized controlled trial deploying AI-CDSS for the management of upper gastrointestinal bleeding (UGIB) with and without an LLM interface within realistic clinical simulations for physician and medical student participants. We find evidence that LLM augmentation improves ease-of-use, that LLM-generated responses with citations improve trust, and HCI varies based on clinical expertise. Qualitative themes from interviews suggest the perception of LLM-augmented AI-CDSS as a team-member used to confirm initial clinical intuitions and help evaluate borderline decisions.
- 12 April 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (1) , E15-E16
Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours—Not so fast!
An abstract is unavailable. This article is available as a PDF only.
- 12 April 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (1) , E15-E16
Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours—Not so fast!
An abstract is unavailable. This article is available as a PDF only.
- 22 March 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (9) , 1062-1081
Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management
Summary: Background: Acute upper gastrointestinal bleeding (UGIB) is a common emergency requiring hospital‐based care. Advances in care across pre‐endoscopic, endoscopic and post‐endoscopic phases have led to improvements in clinical outcomes.Aims: To provide a detailed, evidence‐based update on major aspects of care across pre‐endoscopic, endoscopic and post‐endoscopic phases.Methods: We performed a structured bibliographic database search for each topic. If a recent high‐quality meta‐analysis was not available, we performed a meta‐analysis with random effects methods and odds ratios with 95% confidence intervals.Results: Pre‐endoscopic management of UGIB includes risk stratification, a restrictive red blood cell transfusion policy unless the patient has cardiovascular disease, and pharmacologic therapy with erythromycin and a proton pump inhibitor. Patients with cirrhosis should be treated with prophylactic antibiotics and vasoactive medications. Tranexamic acid should not be used. Endoscopic management of UGIB depends on the aetiology. For peptic ulcer disease (PUD) with high‐risk stigmata, endoscopic therapy, including over‐the‐scope clips (OTSCs) and TC‐325 powder spray, should be performed. For variceal bleeding, treatment should be customised by severity and anatomic location. Post‐endoscopic management includes early enteral feeding for all UGIB patients. For high‐risk PUD, PPI should be continued for 72 h, and rebleeding should initially be evaluated with a repeat endoscopy. For variceal bleeding, high‐risk patients or those with further bleeding, a transjugular intrahepatic portosystemic shunt can be considered.Conclusions: Management of acute UGIB should include treatment plans for pre‐endoscopic, endoscopic and post‐endoscopic phases of care, and customise treatment decisions based on aetiology and severity of bleeding.
- 22 March 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (9) , 1062-1081
Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management
Summary: Background: Acute upper gastrointestinal bleeding (UGIB) is a common emergency requiring hospital‐based care. Advances in care across pre‐endoscopic, endoscopic and post‐endoscopic phases have led to improvements in clinical outcomes.Aims: To provide a detailed, evidence‐based update on major aspects of care across pre‐endoscopic, endoscopic and post‐endoscopic phases.Methods: We performed a structured bibliographic database search for each topic. If a recent high‐quality meta‐analysis was not available, we performed a meta‐analysis with random effects methods and odds ratios with 95% confidence intervals.Results: Pre‐endoscopic management of UGIB includes risk stratification, a restrictive red blood cell transfusion policy unless the patient has cardiovascular disease, and pharmacologic therapy with erythromycin and a proton pump inhibitor. Patients with cirrhosis should be treated with prophylactic antibiotics and vasoactive medications. Tranexamic acid should not be used. Endoscopic management of UGIB depends on the aetiology. For peptic ulcer disease (PUD) with high‐risk stigmata, endoscopic therapy, including over‐the‐scope clips (OTSCs) and TC‐325 powder spray, should be performed. For variceal bleeding, treatment should be customised by severity and anatomic location. Post‐endoscopic management includes early enteral feeding for all UGIB patients. For high‐risk PUD, PPI should be continued for 72 h, and rebleeding should initially be evaluated with a repeat endoscopy. For variceal bleeding, high‐risk patients or those with further bleeding, a transjugular intrahepatic portosystemic shunt can be considered.Conclusions: Management of acute UGIB should include treatment plans for pre‐endoscopic, endoscopic and post‐endoscopic phases of care, and customise treatment decisions based on aetiology and severity of bleeding.